Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

Discover Trametinib as a promising treatment for severe hypertrophic cardiomyopathy in children with RASopathies.

Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The ...

After the 2024 election, political attention turns to governor races in Virginia and New Jersey as well as special election ...

Other approaches that are in development include fibroblast growth factor (FGF) mimetics such as FGF21-targeting candidates ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Most diabetic wound care products are passive dressings, only providing a protective barrier against the external environment ...

This new diet encourages us to eat healthy foods earlier in the day. But how does it work – and do the benefits extend beyond ...

This important study reveals a critical role of the transcription factor NR2F2 in mouse fetal Leydig cell (FLC) differentiation. With elegantly carried out experiments, the authors provide compelling ...

Genetic Signature May Predict Response to Immunotherapy for Non-Small Cell Lung Cancer Feb. 23, 2024 — A new study identified a set of 140 genes that may help predict enhanced disease-free ...